Skip to main content
. 2024 Jun 20;12(6):e01416. doi: 10.1002/rcr2.1416

FIGURE 1.

FIGURE 1

Computed tomography images. (A) Before chemotherapy (August 2022). FDG‐PET showed high uptake of FDG in the left mediastinal lymph node and the left apical tumour. (B) After four courses of chemotherapy with carboplatin, etoposide, and atezolizumab, and then after five courses of atezolizumab maintenance therapy, both tumours shrunk in size. (C) After a total of six courses of atezolizumab maintenance therapy, only the left upper lung tumour was observed to have increased in May 2023. (D) After two courses of second‐line chemotherapy with nogitecan, the left upper lung tumour was further noted to have increased in July 2023. (E) After one course of third‐line chemotherapy with carboplatin and etoposide, the left upper lung tumour was noted to have increased and showed high uptake of FDG in August 2023. CBDCA, carboplatin; ETP, etoposide; FDG‐PET, 18F‐fluorodeoxyglucose positron emission tomography; NGT, nogitecan.